Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Hold” by Analysts

Grifols, S.A. (NASDAQ:GRFS) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research firms have recently weighed in on GRFS. Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. JPMorgan Chase & Co. lowered their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th.

Grifols Stock Up 0.7%

GRFS opened at $9.08 on Thursday. The stock has a market capitalization of $6.24 billion, a price-to-earnings ratio of 47.79, a PEG ratio of 0.37 and a beta of 0.67. The firm has a 50 day moving average price of $8.98 and a 200-day moving average price of $9.47. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20.

Institutional Trading of Grifols

Several large investors have recently added to or reduced their stakes in GRFS. Versant Capital Management Inc increased its holdings in Grifols by 39.5% during the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,584 shares during the last quarter. Peterson Wealth Services boosted its stake in shares of Grifols by 385.8% during the 3rd quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 5,787 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Grifols by 109.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 4,518 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Grifols in the 2nd quarter worth $95,000.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.